Mergers & Acquisitions Mergers & Acquisitions

Illumina offers EU concessions over Grail deal as merger-review clock restarts

US biotech company Illumina has today offered to change the terms of its deal to acquire cancer-testing specialist Grail in a bid to assuage EU competition concerns over the transaction, according to an update to the EU regulator’s website this evening.

The review clock also officially restarted today, after the European

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News